Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that it has entered into a definitive Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, implementing the stapled contingent value rights ("CVRs") plan previously announced on September 29, 2026.

In connection with the execution of the CVR Agreement, Atossa's Board of Directors declared a dividend of one stapled CVR for each share of Atossa common stock outstanding at the close of business on October 19, 2026, the record date. Each share of Atossa common stock issued after the record date and prior to any detachment of the CVRs or expiration of the CVR Agreement will also carry one CVR.